Source: The Prostate Cancer Foundation (PCF)

THE PROSTATE CANCER FOUNDATION ANNOUNCES RECIPIENTS OF THE 2018 PCF YOUNG INVESTIGATOR AWARDS

Total of $6 Million granted to 29 promising young scientists to support innovative research to defeat prostate cancer

The Prostate Cancer Foundation (PCF) announced today that it has granted a total of $6 million to 29 promising early career scientists dedicated to advancing critical research in developing better early detection methods, improving life-saving treatments and finding a cure for prostate cancer. Sponsored by the PCF, the Young Investigator Awards program provides both financial support and a comprehensive career development program to early career scientists with unique approaches and groundbreaking ideas to drive the critical research needed to defeat prostate cancer, a disease that nearly 14 million men worldwide are currently battling.

“We are honored to invest in new cutting-edge ideas for prostate cancer research.  This year’s recipients show great potential for unlocking new discoveries and achieving unprecedented strides toward research leading the way to help countless men affected by the disease,” said Jonathan Simons, MD, PCF’s President and CEO.

As a nonprofit organization committed to globally accelerating the development of new breakthroughs in prostate cancer, the PCF has invested more than $53 million to support 255 young investigators since 2007. The 2018 Young Investigator Awards recipients were selected from a pool of 103 applications from 55 institutions in 11 countries.

Recipients of the PCF Young Investigator Award must demonstrate significant promise for having a long-term and impactful career in the prostate cancer research field. Awardees must be within six years of completing professional scientific training programs and be under the guidance of at least one mentor.  Eleven of the 2018 PCF Young Investigator Awardees are conducting research to improve prostate cancer outcomes in U.S. Veterans.   Additional research focus areas include: novel precision medicine; new treatments and treatment strategies; immunotherapy; studying inherited genetic alterations for those at increased risk; and prostate cancer disparities particularly among African-American men.

The 2018 Young Investigator Awards recipients are:

Name Institution
Saud AlDubayan, MD Harvard: Dana-Farber Cancer Institute
Mohammad Asim, PhD University of Surrey, United Kingdom
Hala Borno, MD University of California, San Francisco
Frank Cackowski, MD, PhD University of Michigan
Megan Caram, MD University of Michigan
Kellie Cotter, PhD University of Berne, Switzerland
Anis Hamid, MBBS Harvard: Dana-Farber Cancer Institute
Jennifer Jones, MD, PhD National Cancer Institute
Saud AlDubayan, MD Harvard: Dana-Farber Cancer Institute
 Salma Kaochar, PhD Baylor College of Medicine
 Sheng-Yu Ku, PhD Weill Cornell Medicine
 Hui Li, PhD  University of California, San Francisco
 Brandon Mahal, MD  Harvard: Dana-Farber Cancer Institute
 Danil Makarov, MD  New York University
 Megan McNamara, MD  Duke University
 Kent Mouw, MD, PhD  Harvard: Dana-Farber Cancer Institute
 Vivek Narayan, MD  University of Pennsylvania
 David Oh, MD, PhD  University of California, San Francisco
 Eileen Parkes, MD, PhD  Queen’s University Belfast, Northern Ireland
 Raquel Perez-Lopez, MD, PhD  Vall d’Hebron Institute of Oncology, Spain
 Sethuramasundaram Pitchiaya, PhD  University of Michigan
 Nicholas Reder, MD, MPH  University of Washington
 Zachery Reichert, MD, PhD  University of Michigan
 Veronica Rodriguez-Bravo, PhD  Thomas Jefferson University
 Joshua Russo, MD, PhD  Harvard: Beth Israel Deaconess Medical Center
 Adam Sharp, MD, PhD  Institute of Cancer Research, United Kingdom
 Min Yuen Teo, MD  Memorial Sloan Kettering Cancer Center
 Vasanthi Viswanathan, PhD  Harvard: Broad Institute of MIT & Harvard
 Scott Wilkinson, PhD  National Cancer Institute
 David Wise, MD, PhD  New York University

For more information about the 2018 Young Investigator Awards recipients, click here.

About the Prostate Cancer Foundation (PCF)

PCF is the world’s leading philanthropic organization funding and accelerating prostate cancer research. Founded in 1993, PCF has raised more than $720 million and provided funding to more than 2,000 research programs at nearly 200 cancer centers and universities. The PCF global research enterprise now extends to 19 countries. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a 20-fold increase in government funding for prostate cancer. For more information, visit www.pcf.org.

#   #   #